Coherus Unveils Its Biosimilar Patient and Provider Support Services

Coherus BioSciences has launched a comprehensive website offering patients and providers support services for its biosimilars.

Coherus BioSciences has launched a comprehensive website offering patients and providers support services designed to answer questions and address needs that may arise when patients begin taking a biosimilar.

“At Coherus Biosciences, we’re committed to ensuring patient access to biologics through high-quality biosimilars,” read the website.

The services include reimbursement support, patient support programs, and provider service programs. Through the reimbursement support feature, patients will be able to verify benefits for their specific insurance coverage, address questions stemming from billing details and claims submissions, and submit or appeal prior authorization determinations.

Coherus is also seeking to reduce out-of-pocket costs for patients who are commercially insured through the Coherus COMPLETE Co-Pay Assistance Program. In addition, Coherus will also be providing its biosimilars to eligible uninsured and underinsured patients through the Patient Assistance Program. Notably, however, patients covered under Medicare or Medicaid will not be eligible to enroll in the Coherus COMPLETE Co-Pay Assistance Program.

Finally, Coherus is also providing a service specifically for providers to have a central repository for all programs and services offered through a single portal. The portal will also allow providers to contact reimbursement specialists to help secure both access and reimbursement for their patients.

“We’re developing high-value biosimilar therapies backed by robust support services so that you and your patients don’t have to choose between quality and cost,” the site states.

Coherus has launched this portal ahead of its November 2018 Biosimilar User Fee Act action date for its proposed pegfilgrastim biosimilar, CHS-1701, referencing Neulasta. While Coherus’ initial filing was met with a Complete Response Letter, in May 2018, the drug maker resubmitted its Biologics License Application to the FDA after including new data from immunogenicity studies.

The pegfilgrastim biosimilar was authorized by the European Commission just last month and will be marketed under the brand name Udenyca.